全文获取类型
收费全文 | 453篇 |
免费 | 20篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 7篇 |
基础医学 | 43篇 |
口腔科学 | 1篇 |
临床医学 | 78篇 |
内科学 | 138篇 |
神经病学 | 15篇 |
特种医学 | 16篇 |
外科学 | 101篇 |
综合类 | 7篇 |
预防医学 | 24篇 |
眼科学 | 1篇 |
药学 | 16篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 5篇 |
2022年 | 7篇 |
2021年 | 23篇 |
2020年 | 6篇 |
2019年 | 20篇 |
2018年 | 18篇 |
2017年 | 16篇 |
2016年 | 13篇 |
2015年 | 10篇 |
2014年 | 29篇 |
2013年 | 23篇 |
2012年 | 32篇 |
2011年 | 24篇 |
2010年 | 11篇 |
2009年 | 17篇 |
2008年 | 24篇 |
2007年 | 23篇 |
2006年 | 33篇 |
2005年 | 35篇 |
2004年 | 42篇 |
2003年 | 16篇 |
2002年 | 29篇 |
2001年 | 7篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1985年 | 2篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有474条查询结果,搜索用时 31 毫秒
471.
In a meta-analysis examining respiratory specimen Gram stain for diagnosis of ventilator-associated pneumonia, absence of bacteria on Gram stain had a high negative predictive value, but a positive Gram stain correlated poorly with organisms recovered in culture. Rapid and accurate diagnosis of ventilator-associated pneumonia (VAP) is a major challenge and no generally accepted gold standard exists for VAP diagnosis. We conducted a meta-analysis to examine the role of respiratory specimen Gram stain to diagnose VAP, and the correlation with final culture results. In 21 studies, pooled sensitivity of Gram stain for VAP was 0.79 (95% confidence interval [CI], .77-0.81; P < .0001) and specificity was 0.75 (95% CI, .73-.78; P < .0001). Negative predictive value of Gram stain for a VAP prevalence of 20%-30% was 91%, suggesting that VAP is unlikely with a negative Gram stain but the positive predictive value of Gram stain was only 40%. Pooled kappa was 0.42 for gram-positive organisms and 0.34 for gram-negative organisms, suggesting fair concordance between organisms on Gram stain and recovery by culture. Therefore, a positive Gram stain should not be used to narrow anti-infective therapy until culture results become available. 相似文献
472.
Sohaib Hashmi Mohamed Noureldin Safdar N. Khan 《Current reviews in musculoskeletal medicine》2014,7(3):193-199
The original 13 Food and Drug Administration industry-sponsored recombinant human bone morphogenetic protein-2 (rhBMP-2) trials investigating its use in spinal fusion all reported no associated adverse events. However, subsequent series of studies began reporting complication rates that were much higher than those that were initially published. Critical analysis of the original rhBMP-2 industry-associated data found systematic alignment favoring positive outcomes with no proven clinical advantage over bone graft. The sources of potential bias leading to inaccurate reporting of original rhBMP-2 efficacy and safety profile include flawed study design, methodological technique, data reporting and analysis, and significant financial conflict of interest. As such, to ensure the integrity of the scientific literature, further measures should be taken by researchers, surgeons, authors, journal editors and reviewers to assess for potential sources of bias. 相似文献
473.
Muhammad Usman Ali Khan Tasleem Akhtar Nadia Naseem Usman Aftab Safdar Hussain Muhammad Shahzad 《Fundamental & clinical pharmacology》2023,37(5):971-982
Rheumatoid arthritis is a chronic systemic inflammatory disease with genetic manifestations. According to recently published case reports, patients taking corticosteroid medication for the management of rheumatoid arthritis develop strongloidiasis and are at high risk of developing associated infections. This study explored the antiarthritic role of ivermectin, a drug used in the treatment of strongyloides and to compare its results with dexamethasone. Thirty-two male Wistar rats were randomly divided into four groups: control, diseased, dexamethasone, and ivermectin groups. Rheumatoid arthritis in all rats except the control group was induced by using complete Freund's adjuvant. After 7 days of rheumatoid arthritis induction, animals were treated with dexamethasone 5 mg/kg and ivermectin 6 mg/kg. Body weight, visual arthritic score, total leukocyte count, differential leukocyte count, proinflammatory genes, and histopathological findings were used to assess the effects of ivermectin on rheumatoid arthritis. Treatment with ivermectin showed a significant reduction in inflammatory cells levels, body weight, and visual arthritic score, indicating an improvement in the degree of inflammation as compared with the diseased group. Treatment with ivermectin and dexamethasone significantly reduced the augmentation in the mRNA expression levels of IL-17, TLR-2, TNF, and NF-κB as a result of arthritic development. Ivermectin treatment also showed a significant reduction in the severity of inflammation and destruction of joints and showed comparable effects to dexamethasone, a corticosteroid used for the treatment of rheumatoid arthritis. Ivermectin has significant antiarthritic properties and can be a novel treatment agent for the management of rheumatoid arthritis patients suffering from strongyloidiasis. 相似文献
474.
Lukas Kaufmann Johannes Pilic Lisa Auinger Anna-Lena Mayer Jasmin Blatterer Johann Semmler-Bruckner Safdar Abbas Khurram Rehman Muhammad Ayaz Wolfgang F. Graier Roland Malli Erwin Petek Klaus Wagner Ali Al Kaissi Muzammil Ahmad Khan Christian Windpassinger 《Clinical genetics》2023,104(4):491-496
Restrictive dermopathy (RD) is a lethal condition caused by biallelic loss-of-function mutations in ZMPSTE24, whereas mutations preserving residual enzymatic activity of the ZMPSTE24 protein lead to the milder mandibuloacral dysplasia with type B lipodystrophy (MADB) phenotype. Remarkably, we identified a homozygous, presumably loss-of-function mutation in ZMPSTE24 [c.28_29insA, p.(Leu10Tyrfs*37)] in two consanguineous Pakistani families segregating MADB. To clarify how lethal consequences are prevented in affected individuals, functional analysis was performed. Expression experiments supported utilization of two alternative translation initiation sites, preventing complete loss of protein function consistent with the relatively mild phenotypic outcome in affected patients. One of these alternative start codons is newly formed at the insertion site. Our findings indicate that the creation of new potential start codons through N-terminal mutations in other disease-associated genes should generally be taken into consideration in the variant interpretation process. 相似文献